Windtree Therapeutics, a struggling biotech firm, faces delisting from Nasdaq after failing to meet the $1 per-share threshold. The company rebranded to focus on holding BNB reserves, but its stock collapsed nearly 98% in the past six months. Windtree’s pivot into digital assets has put its market access at risk.

Leave a Reply